Back to Stock Analysis
Egetis Therapeutics$EGTX.ST
1 research article
By following, you request company-alert emails. Manage or stop them anytime in your account. Privacy.
Research Articles
FDA approves Egetis's Emcitate for the treatment of Monocarboxylate transporter 8 (MCT8) deficiency, a Flerie AB portfolio company
Egetis Therapeutics ($EGTX.ST) • By Leftfield Investing • 2026-09-29